Compare Arqit Quantum Inc (ARQQ) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arqit Quantum Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Arqit Quantum Inc trades at $23.71 (market cap $424.79M), while State Street SPDR S&P Biotech ETF trades at $159.13. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Arqit Quantum Inc nearer its low. Which is the better fit depends on your goals.
| ARQQ | XBI | |
|---|---|---|
Market Cap | $424.79M | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $58.27 | $164.28 |
52-Week Low | $11.78 | $86.92 |
Enterprise Value | $398.10M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARQQ trades at $23.70, up 4.82% today, with a bullish technical signal from moving averages and ADX. The stock shows extreme valuation metrics with a P/S of 352.9 and P/B of 14.9, while fundamentals reveal severe losses: Q1 2026 EPS missed at -$1.99, net income margin is -4,508.1%, and revenue remains minimal at $530K for 2025. Recent news highlights a proof of concept with nLighten and 829% YoY revenue growth in H1 FY26, signaling potential commercial traction in quantum-safe encryption.
Outlook hinges on scaling revenue to justify valuation, with risks from persistent cash burn and high SG&A. Analyst sentiment is split 50/50 buy/hold, reflecting optimism for government/telecom contracts against financial distress. The stock faces volatility near resistance at $25, requiring sustained growth to support bullish momentum.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Arqit Quantum Inc
Arqit Quantum provides advanced cybersecurity software that uses symmetric key agreement technology. Its solutions protect networked devices and data against current and future cyber threats, including quantum attacks.
Read more on ARQQ →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
